Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA 518.80
+2.80 (0.54%)
Aug 3, 2026, 5:24 PM IDT
Can-Fite BioPharma Revenue
In the year 2025, Can-Fite BioPharma had annual revenue of $405.00K USD, down -39.91%. Can-Fite BioPharma had revenue of $203.00K in the half year ending December 31, 2025, a decrease of -42.17%.
Revenue
$405.00K
Revenue Growth
-39.91%
P/S Ratio
17.22
Revenue / Employee
$81.00K
Employees
5
Market Cap
22.23M ILS
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 405.00K | -269.00K | -39.91% |
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
| Dec 31, 2018 | 3.82M | 3.03M | 384.16% |
| Dec 31, 2017 | 789.00K | 624.00K | 378.18% |
| Dec 31, 2016 | 165.00K | 3.00K | 1.85% |
| Dec 31, 2015 | 162.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 467.66K | -278.63K | -37.34% |
| Dec 31, 2010 | 746.29K | -125.25K | -14.37% |
| Dec 31, 2009 | 871.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clal Biotechnology Industries | 11.55M |
| Evogene | 5.82M |
| BioLineRx | 4.43M |
| Geffen Residence & Renewal | 78.00K |
| BioLight Life Sciences | 21.00K |
Can-Fite BioPharma News
- 17 hours ago - Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu - TheFly
- 18 hours ago - Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome - GlobeNewsWire
- 14 days ago - Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewsWire
- 20 days ago - Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment - GuruFocus
- 20 days ago - Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson - TheFly
- 20 days ago - Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study - GuruFocus
- 4 weeks ago - Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial - TheFly